The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure

Irving H Zucker, Liang Xiao, Karla K V Haack

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

CHF (chronic heart failure) is a multifactorial disease process that is characterized by overactivation of the RAAS (renin-angiotensin-aldosterone system) and the sympathetic nervous system. Both of these systems are chronically activated in CHF. The RAAS consists of an excitatory arm involving AngII (angiotensin II), ACE (angiotensin-converting enzyme) and the AT1R (AngII type 1 receptor). The RAAS also consists of a protective arm consisting of Ang-(1-7) [angiotensin-(1-7)], the AT2R (AngII type 2 receptor), ACE2 and the Mas receptor. Sympatho-excitation in CHF is driven, in large part, by an imbalance of these two arms, with an increase in the AngII/AT1R/ACE arm and a decrease in the AT2R/ACE2 arm. This imbalance is manifested in cardiovascular-control regions of the brain such as the rostral ventrolateral medulla and paraventricular nucleus in the hypothalamus. The present review focuses on the current literature that describes the components of these two arms of the RAAS and their imbalance in the CHF state. Moreover, the present review provides additional evidence for the relevance of ACE2 and Ang-(1-7) as key players in the regulation of central sympathetic outflow in CHF. Finally, we also examine the effects of exercise training as a therapeutic strategy and the molecular mechanisms at play in CHF, in part, because of the ability of exercise training to restore the balance of the RAAS axis and sympathetic outflow.

Original languageEnglish (US)
Pages (from-to)695-706
Number of pages12
JournalClinical Science
Volume126
Issue number10
DOIs
StatePublished - May 1 2014

Fingerprint

Renin-Angiotensin System
Heart Failure
Angiotensin Type 1 Receptor
Peptidyl-Dipeptidase A
Angiotensin Type 2 Receptor
Exercise
Paraventricular Hypothalamic Nucleus
Sympathetic Nervous System
Angiotensin II
Hypothalamus
Brain

Keywords

  • Angiotensin II
  • Angiotensin II type 2 receptor (ATR)
  • Angiotensin-(1-7)
  • Angiotensin-converting enzyme
  • Renin-angiotensin system
  • angiotensin-converting enzyme 2
  • heart failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. / Zucker, Irving H; Xiao, Liang; Haack, Karla K V.

In: Clinical Science, Vol. 126, No. 10, 01.05.2014, p. 695-706.

Research output: Contribution to journalReview article

@article{e5aa02533e6f4532b11306e2d3edf625,
title = "The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure",
abstract = "CHF (chronic heart failure) is a multifactorial disease process that is characterized by overactivation of the RAAS (renin-angiotensin-aldosterone system) and the sympathetic nervous system. Both of these systems are chronically activated in CHF. The RAAS consists of an excitatory arm involving AngII (angiotensin II), ACE (angiotensin-converting enzyme) and the AT1R (AngII type 1 receptor). The RAAS also consists of a protective arm consisting of Ang-(1-7) [angiotensin-(1-7)], the AT2R (AngII type 2 receptor), ACE2 and the Mas receptor. Sympatho-excitation in CHF is driven, in large part, by an imbalance of these two arms, with an increase in the AngII/AT1R/ACE arm and a decrease in the AT2R/ACE2 arm. This imbalance is manifested in cardiovascular-control regions of the brain such as the rostral ventrolateral medulla and paraventricular nucleus in the hypothalamus. The present review focuses on the current literature that describes the components of these two arms of the RAAS and their imbalance in the CHF state. Moreover, the present review provides additional evidence for the relevance of ACE2 and Ang-(1-7) as key players in the regulation of central sympathetic outflow in CHF. Finally, we also examine the effects of exercise training as a therapeutic strategy and the molecular mechanisms at play in CHF, in part, because of the ability of exercise training to restore the balance of the RAAS axis and sympathetic outflow.",
keywords = "Angiotensin II, Angiotensin II type 2 receptor (ATR), Angiotensin-(1-7), Angiotensin-converting enzyme, Renin-angiotensin system, angiotensin-converting enzyme 2, heart failure",
author = "Zucker, {Irving H} and Liang Xiao and Haack, {Karla K V}",
year = "2014",
month = "5",
day = "1",
doi = "10.1042/CS20130294",
language = "English (US)",
volume = "126",
pages = "695--706",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "10",

}

TY - JOUR

T1 - The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure

AU - Zucker, Irving H

AU - Xiao, Liang

AU - Haack, Karla K V

PY - 2014/5/1

Y1 - 2014/5/1

N2 - CHF (chronic heart failure) is a multifactorial disease process that is characterized by overactivation of the RAAS (renin-angiotensin-aldosterone system) and the sympathetic nervous system. Both of these systems are chronically activated in CHF. The RAAS consists of an excitatory arm involving AngII (angiotensin II), ACE (angiotensin-converting enzyme) and the AT1R (AngII type 1 receptor). The RAAS also consists of a protective arm consisting of Ang-(1-7) [angiotensin-(1-7)], the AT2R (AngII type 2 receptor), ACE2 and the Mas receptor. Sympatho-excitation in CHF is driven, in large part, by an imbalance of these two arms, with an increase in the AngII/AT1R/ACE arm and a decrease in the AT2R/ACE2 arm. This imbalance is manifested in cardiovascular-control regions of the brain such as the rostral ventrolateral medulla and paraventricular nucleus in the hypothalamus. The present review focuses on the current literature that describes the components of these two arms of the RAAS and their imbalance in the CHF state. Moreover, the present review provides additional evidence for the relevance of ACE2 and Ang-(1-7) as key players in the regulation of central sympathetic outflow in CHF. Finally, we also examine the effects of exercise training as a therapeutic strategy and the molecular mechanisms at play in CHF, in part, because of the ability of exercise training to restore the balance of the RAAS axis and sympathetic outflow.

AB - CHF (chronic heart failure) is a multifactorial disease process that is characterized by overactivation of the RAAS (renin-angiotensin-aldosterone system) and the sympathetic nervous system. Both of these systems are chronically activated in CHF. The RAAS consists of an excitatory arm involving AngII (angiotensin II), ACE (angiotensin-converting enzyme) and the AT1R (AngII type 1 receptor). The RAAS also consists of a protective arm consisting of Ang-(1-7) [angiotensin-(1-7)], the AT2R (AngII type 2 receptor), ACE2 and the Mas receptor. Sympatho-excitation in CHF is driven, in large part, by an imbalance of these two arms, with an increase in the AngII/AT1R/ACE arm and a decrease in the AT2R/ACE2 arm. This imbalance is manifested in cardiovascular-control regions of the brain such as the rostral ventrolateral medulla and paraventricular nucleus in the hypothalamus. The present review focuses on the current literature that describes the components of these two arms of the RAAS and their imbalance in the CHF state. Moreover, the present review provides additional evidence for the relevance of ACE2 and Ang-(1-7) as key players in the regulation of central sympathetic outflow in CHF. Finally, we also examine the effects of exercise training as a therapeutic strategy and the molecular mechanisms at play in CHF, in part, because of the ability of exercise training to restore the balance of the RAAS axis and sympathetic outflow.

KW - Angiotensin II

KW - Angiotensin II type 2 receptor (ATR)

KW - Angiotensin-(1-7)

KW - Angiotensin-converting enzyme

KW - Renin-angiotensin system

KW - angiotensin-converting enzyme 2

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=84893924089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893924089&partnerID=8YFLogxK

U2 - 10.1042/CS20130294

DO - 10.1042/CS20130294

M3 - Review article

VL - 126

SP - 695

EP - 706

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 10

ER -